Kira Pharmaceuticals

What Kira Pharmaceuticals does

Kira Pharmaceuticals is a clinical-stage biotechnology company founded in 2017 that develops complement-targeted biologic therapies for rare immune-mediated diseases. The company operates a proprietary drug discovery platform called LOGIC (Lead identification, Optimization and attribute Generation, In-vivo Confirmation), which is augmented by licensed transgenic humanized animal models from the University of Pennsylvania and the University of Lübeck for target validation and PK/PD prediction. Its lead asset, KP104, is a first-in-class bifunctional biologic combining an anti-C5 monoclonal antibody with a Factor H (FH1-5) fusion protein, enabling simultaneous inhibition of both the alternative and terminal complement pathways with extended half-life and optional subcutaneous administration. KP104 is being evaluated in Phase 2 trials across PNH, IgA nephropathy, C3 glomerulopathy, and SLE-associated thrombotic microangiopathy in the United States, China, Australia, and South Korea, and received FDA Orphan Drug Designation for PNH in July 2022.

The company's broader pipeline comprises nine complement assets spanning hematology, nephrology, neurology, dermatology, and ophthalmology indications, including pre-clinical and discovery-stage candidates KP301, KP501, KP1020, and KP2050. Kira is headquartered in Cambridge, Massachusetts with R&D and operational facilities in Suzhou and Shanghai, China, and clinical operations in Australia. The executive team is recruited from Alexion Pharmaceuticals, Merck, Bristol-Myers Squibb, Takeda, and other major biopharma companies, and the company is backed by venture investors including RA Capital Management, Vivo Capital, Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, Sinopharm Capital, Foresite Capital, and APlus Partners.

Kira has no commercial product revenue and operates as a pre-commercial biotech funded by venture capital, with cumulative disclosed funding of approximately $99.5 million raised across a $46M Series A in November 2020 and a $53.5M Series B+ in January 2021. The intended go-to-market model is traditional pharmaceutical commercialization following regulatory approval, with planned distribution through specialty physician and institution-focused channels targeting rare disease markets. Future revenue is expected from biologic product sales and potentially from out-licensing of pipeline assets or strategic co-development partnerships.

Name

Kira Pharmaceuticals

Legal name

Kira Pharma Company

Website

https://kirapharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Kira Pharmaceuticals is a clinical-stage biotechnology company developing complement-targeted biologic therapies, led by KP104, a bifunctional anti-C5/Factor H biologic in Phase 2 trials for PNH, IgAN, C3G, and SLE-TMA across the US, China, Australia, and South Korea.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals (Complement Therapeutics)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Complement therapeutics
• Biologic drug development
• Rare disease treatments
• Monoclonal antibody therapies
• Clinical-stage biotechnology

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: As a clinical-stage biotech company with investigational agents not yet approved by any health authority, Kira Pharmaceuticals currently has no product revenue. The company is funded through venture capital and will generate revenue through sales of approved biologic therapeutics once regulatory approvals are obtained.
2. Pipeline Development and Licensing: The company is developing a robust pipeline of nine novel complement assets across multiple indications. Future revenue may be generated through out-licensing of pipeline assets or strategic partnerships for co-development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Kira Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops complement-targeted biologic therapies for rare complement-mediated diseases. Using its proprietary LOGIC drug discovery platform, the company advances a pipeline of nine novel complement assets, with lead asset KP104 being a first-in-class bifunctional biologic that simultaneously blocks both the alternative (Factor H) and terminal (C5) complement pathways. The therapies are being developed for indications including PNH, IgA nephropathy, C3 glomerulopathy, and SLE-TMA.

Product overview

Kira Pharmaceuticals is a clinical-stage biotechnology company pioneering a world free from complement disease. The company operates with its LOGIC drug discovery platform and has developed a pipeline of nine novel complement assets. The core product is KP104, a first-in-class bifunctional biologic that simultaneously blocks alternative (Factor H) and terminal (C5) complement pathways. Supporting pipeline assets include KP301 (long-acting mAb for autoimmune inflammatory disorders), KP501 (classical and lectin pathway biologic), and KP1020/KP2050 (bispecific biologics for dry AMD). KP104 is entering Phase 2 clinical trials while earlier-stage assets are in pre-clinical and discovery phases.

Differentiator

Problem solved

Functional benefit

Products and services

• KP104

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• University of Pennsylvania (UPenn)coreStrategic or Co-development PartnerResearch collaboration and licensing agreement with UPenn's Perelman School of Medicine providing access to proprietary transgenic humanized animal models and technology for complement drug discovery. Dr. Wenchao Song serves as Scientific Founder and Chair of Kira's Scientific Advisory Board, and is a professor at UPenn.
• University of LübeckcoreStrategic or Co-development PartnerOngoing sponsored research agreement and collaboration with University of Lübeck's Institute for Systemic Inflammation Research (Professor Jörg Köhl) for preclinical studies in autoimmune disease models. Prof. Köhl serves on Kira's Scientific Advisory Board.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Alexion Pharmaceuticals (AstraZeneca Rare Disease): Alexion pioneered complement therapeutics with Soliris (eculizumab) and Ultomiris (ravulizumab), the dominant C5 inhibitors in PNH and aHUS — Kira's KP104 is being developed explicitly to address limitations of these agents (extravascular hemolysis, breakthrough hemolysis). Alexion is the most direct comparator in complement-mediated rare diseases.
• Apellis Pharmaceuticals: Apellis developed Empaveli/Aspaveli (pegcetacoplan), the first C3 inhibitor approved for PNH, directly competing with Alexion's C5 inhibitors and Kira's KP104. Apellis is also developing complement therapeutics for geographic atrophy (Syfovre) and other indications, making it a key benchmark for complement-focused biotechs.
• Omeros Corporation: Omeros developed narsoplimab (OMS721), a MASP-2 inhibitor targeting the lectin pathway, for IgA nephropathy and other complement-mediated diseases — direct competition for KP104 in the renal basket indication. Omeros is a similarly sized clinical-stage complement biotech.
• Travere Therapeutics: Travere received accelerated approval for Filspari (sparsentan) for IgA nephropathy and is developing late-stage therapies for focal segmental glomerulosclerosis (FSGS), making it a direct competitor for KP104 in IgAN and a benchmark for rare renal disease biotechs.
• ChemoCentryx (Amgen): ChemoCentryx developed Tavneos (avacopan), a C5a receptor inhibitor approved for ANCA-associated vasculitis, and was acquired by Amgen in 2022 for $3.7B. As a complement-pathway biotech that achieved commercialization, it provides a relevant exit-value benchmark for Kira.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is an established rare-disease biotech with a portfolio of enzyme replacement and biologic therapies (e.g., Naglazyme, Vimizim, Voxzogo). It illustrates the commercial scale achievable in rare disease biotech and is comparable to Kira in target-market focus (ultra-rare diseases) and biologic modality, though BioMarin is much larger and diversified.
• Regeneron Pharmaceuticals: Regeneron is a leader in monoclonal antibody engineering (VelocImmune platform) with deep experience in therapeutic biologics. While Regeneron is not exclusively focused on complement, its VelocImmune platform is technically analogous to Kira's LOGIC platform for biologic discovery and its track record in autoimmune/inflammatory biologics is broadly relevant.
• Vertex Pharmaceuticals: Vertex has built a dominant rare-disease franchise (cystic fibrosis) and is expanding into complement-mediated renal diseases via the Alpine Immune Sciences acquisition. Its commercial infrastructure in rare specialty diseases and willingness to pay for clinical-stage complement assets make it both a competitor and a potential acquirer of Kira.
• Takeda Pharmaceutical: Takeda is a global rare-disease leader post-Shire acquisition, with established rare-disease commercial infrastructure in Asia-Pacific including China. Dana Zhang and other Kira executives have Takeda backgrounds, and Takeda is a potential strategic partner or acquirer given its rare-disease focus and Asia presence.

Emerging players

• Alnylam Pharmaceuticals: Alnylam pioneered RNAi therapeutics with an approved rare-disease portfolio. While Alnylam operates in a different therapeutic modality (RNAi vs. biologics), both companies are clinical-stage with lead assets advancing through pivotal trials for rare diseases, and both target genetically validated pathways with limited patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kira-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kira Pharmaceuticals